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Background: The role of adjuvant chemotherapy and the value of molecular biomarkers in bladder cancer have
not been determined. We aimed to assess the predictive and prognostic values of excision repair cross-
complementation 1 (ERCC1) in identifying appropriate patients who may potentially benefit from adjuvant
chemotherapy for bladder cancer.
Methods: A retrospective analysis was performed on 93 patients with completely resected transitional cell
carcinoma of the bladder. ERCC1 expression was assessed by immunohistochemistry. ERCC1 expression was
analyzed in 57 patients treated with adjuvant gemcitabine plus cisplatin chemotherapy and 36 who were not
treated.
Results: Among 93 patients, ERCC1 expression was positive in 54 (58.1%) and negative in 39 (41.9%). ERCC1
positivity was significantly associated with longer survival (adjusted hazard ratio for death, 0.12, 95% confidence
interval [CI] 0.014-0.99; P = 0.049) in the group without adjuvant chemotherapy while ERCC1 positivity was
associated with shorter survival among patients who have received adjuvant chemotherapy (adjusted hazard ratio
for death, 2.64; 95% CI 1.01-6.85; P = 0.047). Therefore, clinical benefit from adjuvant chemotherapy was associated
with ERCC1 negativity as measured by overall survival (test for interaction, P = 0.034) and by disease-free survival
(test for interaction, P = 0.20).
Conclusions: Among patients with completely resected transitional cell carcinoma of the bladder, those with
ERCC1-negative tumors seemed to benefit more from adjuvant gemcitabine plus cisplatin chemotherapy than
those with ERCC1-positive tumors. Future prospective, randomized studies are warranted to confirm our findings.Background
Many patients with locally advanced bladder cancer
relapse and subsequently die of their disease, even
after potentially curative surgery, because of occult
micrometastases present at diagnosis. Perioperative
chemotherapy has been investigated for patients who
undergo cystectomy for locally advanced transitional
cell carcinoma of the bladder, and clinical benefit
from neoadjuvant cisplatin-based chemotherapy has
been demonstrated in several randomized trials [1-3].* Correspondence: hoy.lim@samsung.com
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reproduction in any medium, provided the orAlthough two meta-analyses showed favorable results
for adjuvant chemotherapy for bladder cancer [4,5], no
randomized trial has demonstrated the efficacy of adju-
vant chemotherapy for overall survival because of small
sample size, or early stoppage of patient entry [6-9]. In
practice, however, many physicians administer adjuvant
chemotherapy despite its weak evidence [10,11]. Further
research investigating the effect of adjuvant chemother-
apy on bladder cancer survival is of high importance
considering its current practice .
Cisplatin is the most important adjuvant chemotherapy
agent for bladder cancer and is usually administered with
gemcitabine. Its cytotoxicity is attributed to the forma-
tion of DNA adducts, which cause inter- and intrastrand
cross-linking that inhibits DNA replication. Cisplatin-
induced DNA adducts are removed by the nucleotide-
excision repair pathway, and the excision repair. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Characteristics of 93 patients with urothelial














Node negative 61 (65.6%)
Node positive 32 (34.4%)
Histologic type
Squamous differentiation 11 (11.8%)







Adjuvant chemotherapy (gemcitabine plus cisplatin)
Yes 57 (61.3%)
4 cycles 24 (25.8%)
3 cycles 28 (30.1%)
2 cycles 4 (4.3%)
1 cycle 1 (1.1%)
No 36 (38.7%)
*all patients have metastatic lymph nodes. † 1973 WHO grading.
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in the nucleotide excision repair pathway. Its increased
expression is associated with resistance to cisplatin-based
chemotherapy in various tumor types [12-17].
In addition to its predictive role for cisplatin-based
chemotherapy, ERCC1 has significant prognostic value
because high ERCC1 expression is associated with longer
survival in patients who do not receive chemotherapy after
complete resection for non-small cell lung cancer [15,18].
ERCC1 has also been supported by studies that demon-
strate cancers with extensive geno- mic alterations have
more malignant phenotype and increased growth rates,
and ERCC1 may be representative of the intrinsic DNA
damage-repair ability of the cell [18,19].
In this study, we sought to determine whether ERCC1
protein expression is an important factor in predicting
the clinical outcome of completely resected bladder can-
cer. To assess the predictive and prognostic value of
ERCC1 and to define the subgroup of patients who are
most likely to benefit from adjuvant chemotherapy,




The initial study population comprised of 137 patients
treated with radical cystectomy and bilateral pelvic lym-
phadenectomy as definitive treatment for clinically loca-
lized urothelial cancer of the bladder between January
2004 and December 2010 at Samsung Medical Center
(Seoul, Korea). Of these, 93 patients were included in the
analysis after excluding 12 patients who had not been
completely resected, eight who received neoadjuvant
chemotherapy, 17 patients whose tumors are pTa/pT1
with negative node, and seven who did not have available
tissue for immunohistochemical analysis for ERCC1.
None received pelvic irradiation after complete resection
or had documented residual disease before receiving ad-
juvant chemotherapy. All specimens included in this
study were transitional cell carcinoma.
Adjuvant chemotherapy included a maximum of four
cycles of gemcitabine (1250 mg/m2 on days 1 and 8) plus
cisplatin (70 mg/m2 on day 1) every 21 days. Adjuvant
chemotherapy was given to patients with pathologically
advanced bladder cancer (T3/4 or positive node) between
three to eight weeks after complete resection. The decision
to treat with adjuvant chemotherapy was made after a full
discussion with patients, and was based on pathologic
tumor stage and patient age or performance status.
Clinicopathologic characteristics including age at oper-
ation, sex, histology, tumor stage, and tumor grade were
extracted from medical records. The study was approved
by the Institutional Review Board of Samsung Medical
Center.Immunohistochemistry for ERCC1
To accurately assess the median value of ERCC1 in
urothelial cancer, we also included additional 149
patients with transitional cell carcinoma originating from
completely resected ureter or renal pelvis between Janu-
ary 2004 and December 2010. This resulted in 242
patients for ERCC1 expression analysis.
Representative paraffin blocks, selected by primary
evaluation of haematoxylin-eosin stained slides, were
chosen for tissue microarray (TMA) preparation. Four
tissue cores were collected from each tumor with a sam-
ple punch (0.6 mm in diameter) and placed in four new
recipient paraffin blocks. Each recipient block contained
Figure 1 Representative immunohistochemical staining for ERCC1. Staining intensity was scored as 0, 1, 2 or 3.
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samples as controls and was prepared with agar in our lab.
Immunohistochemistry was carried out on 4-μm tissue
sections using the Bond Polymer Intense Detection System
(VisionBioSystems, VIC, Australia) according to the manu-
facturer's instructions, with minor modifications. In brief,
formalin-fixed, paraffin-embedded tissue sections were
deparaffinized with Bond Dewax Solution (VisionBioSys-
tems) and an antigen-retrieval procedure performed using
Bond ER Solution (VisionBioSystems) for 20 minutes at
100°C. Endogenous peroxidase was quenched by incuba-
tion with hydrogen peroxide for 7 minutes. Sections were
incubated in a Bond-max automatic slide stainer (Vision-
BioSystems) for 15 minutes at ambient temperature with
primary mouse monoclonal antibody against ERCC1
(1:150; 8 F1, Gene Tex, Irvine, CA, USA) labeled using a
biotin-free polymeric horseradish peroxidase (HRP)-linker
antibody conjugate system. Bound peroxidase was visua-
lized using a solution of diaminobenzidine as the chromo-
gen, and nuclei were counterstained with Mayer’s
hematoxylin. Stromal cells around the tumor portion were
used as an internal positive control.
ERCC1 immunohistochemical staining was assessed by
two blinded investigators (J Sung and GY Kwon) who
reviewed the cases simultaneously at a multihead viewing
microscope. Nuclear staining was considered positive.Staining intensity was defined as follows: 0, no staining; 1,
weak; 2, moderate; 3, strong. Quantification of positivity
(0%-100%) was based on an estimate of the percentage of
stained tumor cells in the tissue microarray core. The final
histochemical score (H-score) was obtained by multiplying
staining intensity by percent positivity, giving H-scores
ranging from 0 to 300. An H-score higher than the median
was considered positive.
Statistical analysis
The primary endpoint of overall survival was calculated
from the day of operation to the date of death or final
follow-up. Disease-free survival was defined from the day
of operation to documented diseased recurrence or death
from any cause. Patients without recurrent disease at the
time of analysis were censored for the final follow-up.
The relationships between ERCC1 expression and clini-
copathologic factors were analyzed using a Chi-square test.
Survival curves were generated using the Kaplan-Meier
method, and the log-rank test was used to compare sur-
vival curves according to clinicopathological characteristics
including ERCC1 expression. A multivariate regression
analysis was carried out using Cox’s regression analysis. A
Cox proportional hazards regression model was used to
test for interaction between ERCC1 expression and adju-
vant chemotherapy. All analyses were performed with the
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9.1 (SAS Institute Inc, Cary, NC, USA).
Results
Patient characteristics
Table 1 lists baseline patient characteristics. The median
patient age was 63 years (range, 34–79), and 79 patients
(84.9%) had advanced disease (pathologic T3/4 or positive
node). Eleven patients had transitional cell carcinoma with
squamous differentiation. Of 93 patients who entered the
study, 57 (61.3%) were treated with adjuvant chemotherapy
and all had advanced disease. Among 36 patients without
adjuvant chemotherapy, 22 (61.1%) had advanced disease
and did not receive adjuvant chemotherapy because of old
age, poor performance, patient refusal, or other causes.
Assessment of ERCC1 expression
Figure 1 shows that ERCC1 was localized to the nucleus.
The median H-score was 50 (range, 0–300). Tumors with
an H-score> 50 were deemed ERCC1 positive. Of 93 blad-
der tumors, 54 (58.1%) were ERCC1 positive and 39
(41.9%) were ERCC1 negative. No significant differences
were found in the clinicopathologic parameters between
patients with ERCC1-positive and those with ERCC1-
negative tumors in groups with or without adjuvant












Men 29 (85.3%) 18 (78.3%) 19 (9
Women 5 (14.7%) 5 (21.7%) 1 (5
Age at operation 0.35
≥ 65 years 8 (23.5%) 8 (34.8%) 15 (7
< 65 years 26 (76.5%) 15 (65.2%) 5 (25
T stage 0.68
T1-T2 2 (5.9%) 2 (8.7%) 9 (45
T3-T4 32 (94.1%) 21 (91.3%) 11 (5
N stage 0.48
Node negative 16 (47.1%) 13 (56.5%) 16 (8
Node positive 18 (52.9%) 10 (43.5%) 4 (20
Histologic type 0.64
Squamous differentiation 6 (17.6%) 3 (13.0%) 1 (5
Other types 28 (82.4%) 20 (87.0%) 19 (9
Pathologic grade* 0.74
Grade 2 2 (5.9%) 5(21.7%) 2(10
Grade 3 32 (94.1%) 18 (78.3%) 18 (9
*1973 WHO grading.Overall survival and ERCC1 expression
The 5-year overall survival rate was 56.0% (95% confidence
interval [CI], 51.8%–60.3%) for the total study population.
According to the Cox model adjusted for the multivariate
predictors of survival, ERCC1-positive tumors, compared
with ERCC1-negative tumors, had no prognostic value for
the entire study population (adjusted hazard ratio [HR] for
death, 1.15; 95% CI, 0.55-2.40; P = 0.71).
Prognostic value of ERCC1 expression according to
adjuvant chemotherapy
Among patients without adjuvant chemotherapy, the 5-
year overall survival rate was higher in ERCC1-positive
tumors than in ERCC1-negative tumors (84.0% vs. 49.2%;
P= 0.083) (Table 3, Figure 2a). Other clinical characteris-
tics such as male, positive lymph node, and transitional
cell carcinoma with squamous differentiation had poor
prognostic values by univariate analysis. Results from
multivariate analysis indicate ERCC1 positivity (adjusted
HR for death, 0.12; 95% CI 0.014–0.99; P = 0.049), negative
lymph node (adjusted HR for death, 0.066; 95% CI 0.005–
0.82; P = 0.035), and histologic types other than squamous
cell differentiation (adjusted HR for death, 0.033; 95% CI
0.002-0.62; P = 0.022) were significantly associated with
longer survival. Among patients who were treated with ad-















5.0%) 13 (81.3%) 48 (88.9%) 31 (79.5%)
.0%) 3 (18.8%) 6 (11.1%) 8 (20.5%)
0.24 0.92
5.0%) 9 (56.3%) 23 (42.6%) 17 (43.6%)
.0%) 7 (43.8%) 31 (57.4%) 22 (56.4%)
0.65 0.99
.0%) 6 (37.5%) 11 (20.4%) 8 (20.5%)
5.0%) 10 (62.5%) 43 (79.6%) 31 (79.5%)
0.58 0.13
0.0%) 16 (100%) 32 (59.3%) 29 (74.4%)
.0%) 0 (0%) 22 (40.7%) 10 (25.6%)
0.87 0.69
.0%) 1 (6.3%) 7 (13.0%) 4 (10.3%)
5.0%) 15 (93.8%) 47 (87.0%) 35 (89.7%)
0.69 0.22
.0%) 1 (6.3%) 64 (7.4%) (15.4%)
0.0%) 15 (93.8%) 50 (92.6%) 33 (84.6%)
Table 3 Overall survival in groups without or with adjuvant chemotherapy
No adjuvant chemotherapy group Adjuvant chemotherapy group
No. (%) 5-Y OS rate (%) P No. (%) 5-Y OS rate (%) P
All patients 36 (100) 68.3 57 (100) 52.3
ERCC1 status 0.083 0.074
Positive 20 (55.6) 84.0 34 (59.6) 41.6
Negative 16 (44.4) 49.2 23 (40.4) 71.8
Sex 0.080 0.14
Male 32 (88.9) 70.6 47 (82.5) 46.2
Female 4 (11.1) 50.0 10 (17.5) 77.8
Age at operation 0.40 0.99
≥ 65 years 24 (66.7) 70.0 16 (28.1) 60.3
< 65 years 12 (33.3) 61.1 41 (71.9) 51.2
T stage 0.21 0.57
T1-T2 15 (41.7) 83.6 4 (7.0) 50.0
T3-T4 21 (58.3) 59.2 53 (93.0) 52.9
N stage 0.10 0.73
N0 32 (88.9) 70.9 29 (50.9) 47.7
N1-3 4 (11.1) 50.0 28 (49.1) 59.1
Histologic type 0.088 0.21
Squamous differentiation 2 (5.6) 50.0 9 (15.8) 77.8
Other types 34 (94.4) 69.8 48 (84.2) 46.8
Pathologic Grade* 0.35 0.47
G2 3 (8.3) 100.0 7 (12.3) 71.4
G3 33 (91.7) 65.7 50 (87.7) 50.2
*1973 WHO grading.
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those with ERCC1-negative tumors (P=0.074) (Table 3,
Figure 2b). Multivariate analysis showed that only ERCC1
positivity was significantly associated with shorter survival in
the group with adjuvant chemotherapy (adjusted HR for
death, 2.64; 95% CI 1.01-6.85; P=0.047). Overall, the inter-
action term between ERCC1 expression and adjuvant
chemotherapy was significant for overall survival (P=0.034).
Disease-free survival, ERCC1 expression, and adjuvant
chemotherapy
The 2-year disease-free survival rates for ERCC1-positive
and ERCC1-negative tumors were 64.6% and 44.2%
(P=0.28) in the group without adjuvant chemotherapy and
46.5% and 64.5% (P=0.19) in the group with adjuvant
chemotherapy, respectively (Figure 3). The interaction term
between ERCC1 expression and adjuvant chemotherapy
showed borderline significance for disease-free survival
(P=0.20).
Discussion
In our study, ERCC1 expression provided both prognostic
and predictive information in patients with completelyresected bladder cancer. Among patients with transitional
cell carcinoma of the bladder treated with cystectomy, high
tumoral expression of ERCC1 correlated with longer sur-
vival in patients without adjuvant chemotherapy and was
associated with shorter survival in those with adjuvant
chemotherapy. A statistically significant interaction be-
tween ERCC1 expression and adjuvant chemotherapy indi-
cated potential benefits of adjuvant chemotherapy in
patients with ERCC1-negative tumors.
To date, the role of adjuvant chemotherapy for bladder
cancer has been controversial, with no Level 1 evidence
supporting adjuvant chemotherapy. In fact, the available
data have not demonstrated a clear benefit of adjuvant
chemotherapy. Despite mounting evidence favoring
neoadjuvant chemotherapy [1-3], physicians are reluctant
to adopt its practice as evidenced by only 1.2% of
patients with stage III bladder cancer receiving neoadju-
vant chemotherapy [10]. Nonetheless, 10.4% of patients
from the same cohort received adjuvant chemotherapy,
implying a preference for adjuvant chemotherapy over
neoadjuvant chemotherapy despite a paucity of evidence
[10,11]. Such ubiquitous practice might be attributed to
two beliefs: that adjuvant chemotherapy could be given
Figure 3 Disease-free survival. Without adjuvant chemotherapy
(a), with adjuvant chemotherapy (b) (interaction P = 0.20).
Figure 2 Overall survival. Without adjuvant chemotherapy (a), with
adjuvant chemotherapy (b) (interaction P= 0.034).
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thereby preventing low-risk patients from unnecessary
cytotoxicity; and that up-front surgery increases the
chances of curing patients with drug-resistant diseases.
In order to strengthen evidence-based practice for adju-
vant chemotherapy, further research including rigorous
study designs and methodologies are warranted.
A significant strength of this study was the appropriate
selection of patients who could potentially benefit from
adjuvant chemotherapy based on ERCC1 expression. The
target populations in previous adjuvant trials were heteroge-
neous, ranging from T1-T2 disease to node positive disease,
and defined only by pathologic stage. A recent prospective
study used p53 expression as a molecular marker for select-
ing a target population for adjuvant chemotherapy [8].Patients whose tumors were p53-positive were randomly
assigned to adjuvant chemotherapy or to observation, and
those with p53-negative tumors were all assigned to obser-
vation. Although this trial failed to demonstrate the prog-
nostic and predictive value of p53 due to a high patient
refusal rate or lower than expected event rate, the attempt
to use a molecular marker in adjuvant chemotherapy is
noteworthy. Further molecularly targeted adjuvant chemo-
therapy should be investigated.
ERCC1 is a component of the nucleotide excision repair
pathway, which is essential for the repair of DNA adducts
induced by cisplatin-based therapy. Several studies have
shown that high ERCC1 expression is a good prognostic
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also a predictor for poor clinical outcome in patients with
cisplatin-based chemotherapy for various tumor types
[12,14,15,18]. ERCC1 was also previously evaluated in meta-
static bladder cancer, and high ERCC1 mRNA or protein
expression correlated with poor prognosis in patients trea-
ted with cisplatin-based chemotherapy [20-22]. In muscle-
invasive bladder cancer, cisplatin-based chemoradiation
therapy showed better efficacy for ERCC1-negative tumors
than ERCC1-positive tumors [23]. Hoffmann et al. demon-
strated that high ERCC1 gene expressions were associated
with inferior progression-free survival after cisplatin-based
adjuvant chemotherapy for locally advanced bladder cancer
[24]. In the present study, the different prognostic values of
ERCC1 according to the history of adjuvant gemcitabine
plus cisplatin chemotherapy were confirmed in patients
with completely resected bladder cancer.
A limitation of our study includes different patient char-
acteristics between two groups with or without adjuvant
chemotherapy owing to the retrospective nature of the
study. However, such difference and bias which can poten-
tially influence study results were minimized because the
value of ERCC1 expression was analyzed independently in
each group. In addition, the adjuvant chemotherapy was
homogenous with an identical regimen of gemcitabine plus
cisplatin.
In summary, we have demonstrated that ERCC1 may
potentially be a novel biomarker with clinical predictive and
prognostic values in completely resected bladder cancer.
Those who have bladder cancer with low ERCC1 expression
are more likely to benefit from adjuvant gemcitabine plus
cisplatin chemotherapy. Further researches including pro-
spective randomized studies are warranted to confirm our
findings.Conclusions
ERCC1 expression has a different prognostic nature
according to the history of adjuvant chemotherapy:
ERCC1-positivity is associated with poorer prognosis in
the group with adjuvant chemotherapy while it has better
prognosis in those without adjuvant chemotherapy. In
bladder cancer, the relevance of ERCC1 expression as a
biomarker selecting patients for adjuvant chemotherapy
should be confirmed in further prospective studies.
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